What you carry at this position in your DNA and what research says about it.
Dopamine Receptor Sensitivity: 5/10 evidence, 57 publications.
You're viewing every possible genotype for this variant.
None of these is your result. Use the genotype toggle to compare them, then sign up and upload your DNA to see which one is yours.
Sample genotype (not yours): C/C
Higher Dopamine Sensitivity and Varied Medication Response
A stronger response to dopamine signaling is linked to better outcomes with certain antipsychotic medications. However, this increased sensitivity may also elevate the risk of nicotine dependence and obsessive-compulsive traits.
What this genotype means: Better response to olanzapine; Higher risk of nicotine dependence; Increased risk of obsessive-compulsive traits.
Sample genotype (not yours): C/T
Typical Dopamine Sensitivity and Balanced Behavioral Risks
A balanced mix of the high-affinity glycine and lower-affinity serine receptors results in typical dopamine signaling. This intermediate profile generally carries average baseline risks for addiction and obsessive-compulsive traits.
What this genotype means: Typical dopamine signaling; Moderate response to olanzapine; Slightly increased risk of levodopa-induced hallucinations.
Sample genotype (not yours): T/T
Lower Dopamine Sensitivity with Protective Behavioral Traits
Receptors with lower dopamine affinity are associated with a reduced risk of nicotine dependence and obsessive-compulsive traits. However, this profile may lead to a less optimal response to certain antipsychotic medications.
What this genotype means: Lower risk of nicotine dependence; Lower risk of obsessive-compulsive traits; Increased risk of levodopa-induced side effects.
Gene function and biological role
Gene Function: The DRD3 gene encodes the dopamine receptor D3, a vital protein in the brain's reward, motivation, and motor control pathways [1]. Unlike some dopamine receptors that promote high alertness, the D3 subtype often exerts a moderating or calming influence on neural circuits [2]. It is highly expressed in the limbic system, which regulates emotions, mood, and reward-seeking behaviors [3]. Variations in this gene can alter how strongly the brain responds to dopamine signals, influencing personality traits and psychiatric drug responses [4].
Variant Impact: The rs6280 variant represents a missense mutation in the first exon of the DRD3 gene, resulting in a change from serine to glycine at position 9 of the receptor protein [1]. This amino acid substitution occurs in the extracellular N-terminal domain, directly affecting how the receptor binds to dopamine [2]. The glycine-encoding C allele produces a receptor with significantly higher dopamine affinity and more robust intracellular signaling compared to the serine-encoding T allele [3]. Consequently, this single change alters the sensitivity of the brain's dopamine pathways, impacting executive function, addiction vulnerability, and response to psychiatric medications [4].
Key Insight: The C allele of this variant increases the dopamine receptor's binding affinity for dopamine by four- to five-fold, significantly altering reward sensitivity.
Location: DRD3. Chromosome 3 · 3q13.31 · 114.2 Mb
Estimated prevalence by population
Global 23.6%; European 10.7%; African 53.4%; East Asian 9.1%; South Asian 16.8%; Americas 20.6%; Ashkenazi 8.6%; Finnish 11.4%; Middle Eastern 15.3%; Amish 12.4%.
Estimated CC genotype frequency.
Global 43.4%; European 44.0%; African 39.4%; East Asian 42.1%; South Asian 48.4%; Americas 49.6%; Ashkenazi 41.4%; Finnish 44.8%; Middle Eastern 47.6%; Amish 45.6%.
Estimated CT genotype frequency.
Global 33.0%; European 45.3%; African 7.3%; East Asian 48.7%; South Asian 34.9%; Americas 29.9%; Ashkenazi 50.1%; Finnish 43.8%; Middle Eastern 37.1%; Amish 42.0%.
Estimated TT genotype frequency.
Showing effects for C/C genotype
Pharmacogenomics
Antidepressant & Psychiatric Drug Response
Antipsychotic Response. Evidence: 3/10. Source: PMID 18320559. Stronger Response.
Neurology & Mental Health
Addiction & Reward
Nicotine Dependence. Evidence: 3/10. Source: PMID 18348205. Increased Risk.
Cognitive Performance
Executive Function. Evidence: 3/10. Source: PMID 18351593. Poorer Performance.
Anxiety & Stress Disorders
Obsessive-Compulsive Disorder. Evidence: 3/10. Source: PMID 16583407. 2.4x Higher Risk.
Neurodegenerative Diseases
Levodopa Side Effects. Evidence: 5/10. Source: PMID 30794329. Typical Risk.
Showing effects for C/T genotype
Antipsychotic Response. Evidence: 3/10. Source: PMID 18320559. Typical Response.
Executive Function. Evidence: 3/10. Source: PMID 18351593. Typical.
Obsessive-Compulsive Disorder. Evidence: 3/10. Source: PMID 16583407. Typical Risk.
Levodopa Side Effects. Evidence: 5/10. Source: PMID 30794329. Hallucination Risk.
Showing effects for T/T genotype
Nicotine Dependence. Evidence: 3/10. Source: PMID 18348205. Typical Risk.
Executive Function. Evidence: 3/10. Source: PMID 18351593. Better Performance.
Levodopa Side Effects. Evidence: 5/10. Source: PMID 30794329. Toxicity Risk.
What this genotype means for the people who carry it
Sample genotype: CC (Homozygous)
Dopamine receptors with two copies of the glycine-encoding C allele exhibit a four- to five-fold higher affinity for dopamine [1]. This heightened sensitivity translates to a more pronounced reward response in the brain's striatum during reinforcing activities [2]. Clinically, this genotype is strongly associated with a significantly better therapeutic response to the antipsychotic medication olanzapine, leading to greater remission of positive symptoms [3]. On the other hand, the same high-affinity state is linked to a higher risk of developing nicotine dependence [4]. Furthermore, research suggests a 2.4-fold increased likelihood of obsessive-compulsive personality disorder in patients with major depression [2]. Executive functioning tasks, such as those measuring cognitive flexibility, may also be more challenging for those with this high-sensitivity profile [1].
Better response to olanzapine; Higher risk of nicotine dependence; Increased risk of obsessive-compulsive traits.
Sample genotype: CT (Heterozygous)
Carrying one copy of each allele produces a mixture of dopamine D3 receptors with varying binding strengths [1]. This intermediate receptor profile generally results in typical executive functioning and cognitive flexibility [1]. While the response to certain antipsychotic medications like olanzapine is not as pronounced as in those with the CC genotype, it remains within the typical range [2]. There is a slightly elevated risk of nicotine dependence compared to the TT genotype, but it is less pronounced than in CC homozygotes [3]. When treated with Parkinson's medications like levodopa, there is a documented increase in the likelihood of experiencing visual hallucinations [4]. Overall, this heterozygous state represents a common genetic baseline with balanced behavioral and therapeutic profiles [5].
Typical dopamine signaling; Moderate response to olanzapine; Slightly increased risk of levodopa-induced hallucinations.
Sample genotype: TT (Homozygous)
Dopamine receptors composed entirely of the serine-encoding T allele display lower binding affinity for dopamine [1]. This lower sensitivity appears to protect against hyperdopaminergic responses, resulting in a significantly lower risk of nicotine dependence [2]. Additionally, this genotype is associated with a lower likelihood of developing obsessive-compulsive personality disorder [3]. Cognitive performance, particularly on executive functioning tasks that require mental flexibility, tends to be stronger with this lower-affinity profile [1]. However, individuals with this genotype may experience a slower or less complete response to antipsychotic therapies such as olanzapine [4]. There is also an increased risk of experiencing gastrointestinal toxicity and hallucinations if treated with levodopa for Parkinson's disease [5].
Lower risk of nicotine dependence; Lower risk of obsessive-compulsive traits; Increased risk of levodopa-induced side effects.
Variants with shared genetic architecture
rs1076560 · DRD2 Gene · Chr 11 · Dopamine and Addiction Risk
rs1800497 · ANKK1 Gene · Chr 11 · Dopamine Receptor Density
rs1803274 · BCHE Gene · Chr 3 · Alzheimer's Disease Risk
Dopamine receptor D3 (DRD3) gene rs6280 variant and risk for restless legs syndrome.
Content updated August 2026.
ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.
Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026
Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com